TheraCode GmbH acquires JPT Peptide Technologies
Published on 20/05/2022
Berlin/Germany, May 7, 2009. - TheraCode GmbH a wholly owned subsidiary of BioNTech AG (Mainz, Germany), a biotech company developing novel personalized immunotherapy approaches today announced the acquisition of all shares of JPT Peptide Technologies GmbH (JPT) from Jerini AG (Berlin, Germany).
JPT, formerly a fully owned subsidiary of Jerini AG, is an integrated provider of innovative peptide based research tools and services for biomarker discovery, immune monitoring and vaccine development. The acquisition will enable JPT's accelerated expansion into a globally leading, quality service provider for high-content peptide arrays, peptide pools, and peptide libraries for all development phases of novel vaccines. Under the direction of the former Managing Director Dr. Holger Wenschuh, the unit will be continued as JPT Peptide Technologies GmbH retaining all production facilities, employees and contractual obligations of the former company. "The investment in JPT not only provides us with access to its unique and proprietary portfolio of peptide technologies, it will also accelerate JPT's continued growth, increase its visibility and further improve its well recognized services to an international client base" said Prof. Dr. Ugur Sahin, CEO of BioNTech AG, adding, "our main focus will be the creation of a globally acting innovative service provider for value-added peptide tools in immunology, proteomics and signal transduction". Helmut Jeggle, chair of the supervisory board of BioNTech commented "The acquisition of JPT endows BioNTech with complementary expertise of high synergistic potential, which will strengthen its unique portfolio of proprietary targets and technologies. This is an important step in our long-term strategy to build an excellent and competitive company providing comprehensive technology platforms for drug and biomarker development."
About BioNTech AG
BioNTech AG is a "spin-off"-company of the Johannes Gutenberg University located in Mainz, Germany. The company, which is financed by MIG Fonds and AT Impf GmbH (a wholly owned company of Dr. Andreas & Dr. Thomas Strüngmann), owns four subsidiaries, Ribological, UniCell, Tulip and TheraCode. BioNTech is dedicated to the development of innovative molecular immunotherapies and biomarker based diagnostic approaches for individualized treatment of cancer and other severe human diseases.
About JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH is a leading provider of peptide-based research tools for applications focusing on cellular and humoral immune response monitoring, vaccine development, peptide biomarker discovery, and enzyme profiling. Using its patented high-throughput synthesis and screening platform, SPOTTM its peptide microarray technology, PepStarTM, PepMixTM, a new approach for antigen specific T-cell stimulation and PepTrackTM a novel approach to create peptide libraries for specific use in T-cell assays, JPT has developed a series of innovative products and services to facilitate the development of novel immunotherapies and immune-monitoring tools. JPT's ability to produce highly complex peptide libraries coupled with its peptide array technology enables, for the first time, the discovery and profiling of B- and T-cell epitopes on a proteome-wide level. In addition, this capability facilitates the development of tools to monitor the immune status of diverse patient populations suffering from infectious and autoimmune diseases, allergies, and cancer.
For further information please contact:
BioNTech AG
Prof. Dr. Ugur Sahin, CEO
BioNTech AG
Langenbeckstr. 8
D-55131 Mainz/Germany
Email: sahin@uni-mainz.de
Tel: +49 (0) 6131-3933456
FAX: +49 (0) 6131-3933343
JPT Peptide Technologies GmbH
Dr. Holger Wenschuh
Managing Director
Volmerstr. 5
D-12555 Berlin/Germany
Tel: +49 (0) 30-63927880
Fax: +49 (0) 30-63925501
E-mail: wenschuh@jpt.com
Web: www.jpt.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.